Takeda Pharmaceutical Company Limited (NYSE:TAK - Get Free Report) shares traded up 3.1% during trading on Monday . The company traded as high as $15.05 and last traded at $14.86. 2,662,226 shares were traded during trading, an increase of 46% from the average session volume of 1,828,393 shares. The stock had previously closed at $14.41.
Takeda Pharmaceutical Trading Up 1.2 %
The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.72 and a current ratio of 1.31. The stock has a market cap of $48.29 billion, a price-to-earnings ratio of 37.94, a price-to-earnings-growth ratio of 0.24 and a beta of 0.46. The company's 50 day simple moving average is $13.55 and its two-hundred day simple moving average is $13.91.
Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last announced its quarterly earnings results on Thursday, January 30th. The company reported $0.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.34 by $0.08. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. Research analysts expect that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current fiscal year.
Institutional Inflows and Outflows
Several hedge funds have recently modified their holdings of the business. US Bancorp DE boosted its holdings in Takeda Pharmaceutical by 11.9% in the third quarter. US Bancorp DE now owns 102,588 shares of the company's stock worth $1,459,000 after purchasing an additional 10,925 shares in the last quarter. QRG Capital Management Inc. lifted its position in shares of Takeda Pharmaceutical by 4.5% in the third quarter. QRG Capital Management Inc. now owns 282,154 shares of the company's stock worth $4,012,000 after buying an additional 12,035 shares during the last quarter. Summit Global Investments boosted its stake in shares of Takeda Pharmaceutical by 86.0% during the 3rd quarter. Summit Global Investments now owns 415,558 shares of the company's stock worth $5,909,000 after acquiring an additional 192,143 shares in the last quarter. Gold Investment Management Ltd. increased its holdings in shares of Takeda Pharmaceutical by 2.0% during the 3rd quarter. Gold Investment Management Ltd. now owns 73,204 shares of the company's stock valued at $1,049,000 after acquiring an additional 1,428 shares during the last quarter. Finally, Assetmark Inc. raised its stake in shares of Takeda Pharmaceutical by 5.9% in the 3rd quarter. Assetmark Inc. now owns 80,982 shares of the company's stock valued at $1,152,000 after acquiring an additional 4,500 shares in the last quarter. Institutional investors and hedge funds own 9.17% of the company's stock.
About Takeda Pharmaceutical
(
Get Free Report)
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.
Featured Articles
Before you consider Takeda Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Takeda Pharmaceutical wasn't on the list.
While Takeda Pharmaceutical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
